NCT06518551 2025-12-11Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMDana-Farber Cancer InstitutePhase 1/2 Recruiting49 enrolled
NCT06785415 2025-09-30Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaMayo ClinicPhase 1/2 Recruiting37 enrolled